ROBERT R. RUFFOLO - 01 Jul 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role: Director
Signature: /s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Jul 2021
Net transactions value: -$66,082
Form type: 4
Filing time: 02 Jul 2021, 16:16:05 UTC
Previous filing: 28 Jun 2021
Next filing: 05 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGTX	Common Stock	Options Exercise	$3,848	+6,750		$0.5700	6,750	01 Jul 2021	Direct	F1
transaction	SGTX	Common Stock	Sale	$69,930	-6,750	-100%	$10.36^*	0	01 Jul 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGTX	Stock Option (Right to Buy)	Options Exercise	$0	-6,750	-12%	$0.000000	48,805	01 Jul 2021	Common Stock	6,750	$0.5700	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2	The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.